Price
$5.2
Increased by +4.21%
Dollar Volume
595.41 K
ADR%
9.8
Earnings Report Date (estimate)
Mar 8, 23 (-0.9)
Market Cap.
93.06 M
Shares Float
9.63 M
Shares Outstanding
17.90 M
Beta
1.18
Price / Earnings
-1.42
BPR
261.25
20D Range
2.50 5.25
50D Range
2.36 5.25
200D Range
2.00 7.84
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -1.35
Decreased by -90.14%
-1.13
Decreased by -19.47%
Aug 11, 22 -1.08
Increased by +29.41%
-0.83
Decreased by -30.12%
May 12, 22 -0.80
Increased by +38.46%
-0.81
Increased by +1.23%
Mar 10, 22 -0.76
Increased by +31.53%
-0.69
Decreased by -10.14%
Nov 9, 21 -0.71
Increased by +37.72%
-1.11
Increased by +36.04%
Aug 11, 21 -1.53
Increased by +8.93%
-1.22
Decreased by -25.41%
May 13, 21 -1.30
Increased by +40.91%
-1.03
Decreased by -26.21%
Mar 11, 21 -1.11
Increased by +81.50%
-1.25
Increased by +11.20%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-13.08 M
Decreased by -95.44%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-10.47 M
Increased by +7.45%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-7.57 M
Increased by +5.33%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-7.15 M
Decreased by -51.38%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-6.69 M
Decreased by -77.76%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-11.31 M
Decreased by -287.10%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-8.00 M
Decreased by -140.93%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-4.72 M
Decreased by -47.90%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.